Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Tradit Complement Med ; 9(1): 1-4, 2019 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30671360

RESUMEN

The aim of this work was to evaluate the inhibitory activities of different extracts of Asparagus racemosus Willd on α - amylase and α - glucosidase at varying concentrations. Diabetes mellitus is a clinical condition characterized by hyperglycaemia in which an elevated amount of glucose circulates in the blood plasma. α - amylase and α - glucosidase inhibitors are used to achieve greater control over hyperglycemia in type 2 diabetes mellitus. This study is to treat the diabetes using natural resources. We aimed to evaluate of Asparagus racemosus Willd by digestive enzymes inhibitory activity. n-hexane, chloroform, ethyl acetate, methanol, and aqueous was used to extract the root of the Asparagus racemosus Willd. The different extracts were then used to study its digestives enzymes activity α-amylase and α - glucosidase inhibitory activity. The significant inhibitory effect of α-amylase and α - glucosidase enzyme and exhibited lower inhibitory activity than acarbose was extracted by the ethyl acetate and aqueous extracts of the plant. Flavonoids, Tannins and phenolic, Saponins, Amino acids, Protein are the major phytochemical constituents present. The total flavonoid content plant extracts of ethyl acetate and aqueous showed dose dependent 23.45 ± 1.33 mg rutin equivalent/g and 25.81 ± 0.82 mg rutin equivalent/g respectively. The total triterpenoids content plant extracts of ethyl acetate, aqueous showed dose dependent 109.8 ± 5.6 mg ursolic acid/g and 95.6 ± 7.5 mg ursolic acid/g respectively. The antidiabetic potential and to develop medicinal preparations and nutraceuticals and function foods for diabetes has revealed.

2.
Artif Cells Nanomed Biotechnol ; 45(2): 364-371, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-27002542

RESUMEN

Olanzapine (OLZ) is a typical anti-psychotic drug, which is highly lipophilic in nature, belongs to Biopharmaceutical Classification System (BCS) class II category. Though OLZ is an effective agent in the treatment of Schizophrenia, but it exhibits poor bioavailability (57%) due to extensive first-pass metabolism resulted in high dose is required to achieve therapeutic concentration in brain. Emerging evidences are indicating that high dose administration of OLZ may cause Extrapyramidal symptoms (EPS) in the psychotic patients. Hence, the present study is designed to develop Olanzapine solid lipid (OLZ-SLNs) using minimal dose of OLZ thereby enhancing the brain efficacy as well as to reduce the side effects associated with OLZ. OLZ-SLNs have been prepared by "solvent diffusion method" using lipids, such as glyceryl monostearate (GMS), tripalmitin (TP), Tween 80, and Stearyl amine as positive charge inducer. The prepared OLZ-SLNs were subjected to particle size analysis, zeta potential, and poly dispersity index measurement by using Malvern Zetasizer. Pharmacokinetics assessments of OLZ-SLNs were carried in conscious male Wistar rats through intravenous administration. Results have shown that average particle size and zeta potential of SLNs of GMS and TP were ranged from 165.1 ± 2.2 to 110.5 ± 0.5 and 35.29 ± 1.2 and 66.50 ± 0.7 mV, respectively. Relative bioavailability of OLZ in the brain was increased up to 23-fold and clearance was decreased when OLZ-SLNs while administrated intravenously. The area under the curve (AUC) and mean residence time (MRT) of OLZ-SLNs in brain were higher than OLZ suspension. These results indicate that SLNs are a promising drug delivery for OLZ. It may be an effective tool to enhance the bioavailability of OLZ in the brain with less dose administration, which could reduce the EPS associated with OLZ.


Asunto(s)
Benzodiazepinas , Encéfalo/metabolismo , Sistemas de Liberación de Medicamentos/métodos , Lípidos , Nanopartículas/química , Animales , Benzodiazepinas/química , Benzodiazepinas/farmacocinética , Benzodiazepinas/farmacología , Lípidos/química , Lípidos/farmacocinética , Lípidos/farmacología , Masculino , Olanzapina , Ratas , Ratas Wistar
3.
Indian J Pharmacol ; 49(4): 275-281, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29326487

RESUMEN

OBJECTIVES: Snakebites are a significant and severe global health problem. Till date, anti-snake venom serum is the only beneficial remedy existing on treating the snakebite victims. As antivenom was reported to induce early or late adverse reactions to human beings, snake venom neutralizing potential for Cyclea peltata root extract was tested for the present research by ex vivo and in vivo approaches on Naja naja toxin. MATERIALS AND METHODS: Ex vivo evaluation of venom toxicity and neutralization assays was carried out. The root extracts from C. peltata were used to evaluate the Ex vivo neutralization tests such as acetylcholinesterase, protease, direct hemolysis assay, phospholipase activity, and procoagulant activity. Gas chromatography-mass spectrometry (GC-MS) analysis from root extracts of C. peltata was done to investigate the bioactive compounds. RESULTS: The in vivo calculation of venom toxicity (LD50) of N. naja venom remained to be 0.301 µg. C. peltata root extracts were efficiently deactivated the venom lethality, and effective dose (ED50) remained to be 7.24 mg/3LD50 of N. naja venom. C. peltata root extract was found effective in counteracting all the lethal effects of venom. GC-MS analysis of the plant extract revealed the presence of antivenom compounds such as tetradecanoic and octadecadienoic acid which have neutralizing properties on N. naja venom. CONCLUSION: The result from the ex vivo and in vivo analysis indicates that C. peltata plant root extract possesses significant compounds such as tetradecanoic acid hexadecanoic acid, heptadecanoic acid, and octadecadienoic acid which can counteract the toxins present in N. naja.


Asunto(s)
Antivenenos/uso terapéutico , Cyclea , Venenos Elapídicos/antagonistas & inhibidores , Extractos Vegetales/uso terapéutico , Raíces de Plantas , Mordeduras de Serpientes/tratamiento farmacológico , Acetilcolinesterasa/metabolismo , Animales , Antivenenos/aislamiento & purificación , Antivenenos/farmacología , Relación Dosis-Respuesta a Droga , Hemólisis/efectos de los fármacos , Hemólisis/fisiología , Ratones , Naja , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/farmacología , Mordeduras de Serpientes/enzimología
4.
Phytother Res ; 26(4): 617-9, 2012 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21915932

RESUMEN

Aloe vera gel is used traditionally for the treatment of skin diseases, including psoriasis. An ethanolic extract of the gel was assessed for antipsoriatic activity using a mouse tail model of psoriasis. The extract produced a significant differentiation in the epidermis, as seen from its degree of orthokeratosis (85.07 ± 3.36%) when compared with the negative control (17.30 ± 4.09%). This was equivalent to the effect of the standard positive control, tazarotene (0.1%) gel, which showed a 90.03 ± 2.00% degree of orthokeratosis. The ethanolic extract of Aloe vera leaf gel also produced a significant increase in relative epidermal thickness when compared with the control group, whereas the standard tazarotene showed no change. Taken together, the extract showed an overall antipsoriatic activity of 81.95%, compared with 87.94 for tazarotene, in the mouse tail model for psoriasis.


Asunto(s)
Aloe/química , Ácidos Nicotínicos/uso terapéutico , Fitoterapia , Extractos Vegetales/uso terapéutico , Hojas de la Planta/química , Psoriasis/tratamiento farmacológico , Animales , Diferenciación Celular , Fármacos Dermatológicos/uso terapéutico , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Epidermis/efectos de los fármacos , Epidermis/patología , Etanol/química , Queratosis/tratamiento farmacológico , Queratosis/patología , Masculino , Ratones , Psoriasis/patología , Cola (estructura animal)/efectos de los fármacos , Cola (estructura animal)/patología
5.
Indian J Pharmacol ; 43(4): 455-9, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21845005

RESUMEN

OBJECTIVE: To evaluate the antidiabetic activity of ethanolic extract of Dioscorea alata in glucose loaded and alloxan induced diabetic rats. MATERIALS AND METHODS: The authenticated tubers of D. alata (DA) (JSSCPDP/2008/157) were collected from Dharmapuri, Tamil Nadu. The ethanol extract was tested for hypoglycemic activity in normal rats. In oral glucose tolerance test, glucose (3 g/kg, p.o.) was administered to non diabetic control, metformin (250 mg/kg, p.o.) and DA extract (100 and 200 mg/kg, p.o.) to treat treated rats. Diabetes mellitus was induced by alloxan monohydrate (120 mg/kg, i.p.) in physiological saline after overnight fasting for 18 hours. DA extract (100 and 200 mg/kg, p.o.) and standard drug metformin (250 mg/kg, p.o.) were administered to diabetic rats for 21 days. Fasting blood glucose level and changes in body weight were measured on days 0, 7, 14, and 21. At the end of 21(st) day, serum lipid profile, total protein, albumin, and creatinine were assessed. RESULTS: In glucose loaded normal rats, the treatment with the extract of DA had shown a highly significant reduction (P < 0.001) in blood glucose levels at the doses of 100 and 200 mg/kg, respectively. The extract did not produce hypoglycemic activity at both the dose levels in normal, fasted rats. In alloxan induced diabetic rats, the body weight of the DA extract treated animals had shown a significant increase (P < 0.001) after 21 days treatment. The blood glucose level was reduced significantly by 47.48% and 52.09% after 21 days treatment at dose levels 100 and 200 mg/kg, respectively. Serum lipid levels, total protein, albumin, and creatinine were reversed toward near normal in treated rats as compared to diabetic control. CONCLUSION: The results indicate that ethanol extract of DA tubers possesses significant antidiabetic activity.

6.
Anc Sci Life ; 27(2): 38-43, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22557268

RESUMEN

The use of metals and minerals is predominant in siddha system of medicine. As per siddha concept, peptic ulcer is known as Valigunmam, the basic abnormality appears to be the derangement of metabolism in the stomach and duodenum resulting in malfunctioning of the secretory process of gastric mucosa. Chendooram is a group of siddha drugs which is used for anemia, obesity, rheumatic diseases; abdominal tumours etc.During the present study standardized Kantha chendooram was selected and evaluated for its anti-ulcer activity, which could not be attempted by researchers earlier.

7.
Anc Sci Life ; 25(3-4): 67-70, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22557209

RESUMEN

Siddha system of medicine is one of the ancient systems of medicine in India. According to Siddhars, peptic ulcer is known as Valigunmam with its signs and symptoms as detailed in Siddha literature matching modern terminology of peptic ulcer. Bhasma refers to calcinated metals and minerals. During this study the Bhasma of Musa paradisiaca Linn, is prepared and evaluated for its antiulcer effect in albino wistar rats which could not be attempted by researchers earlier.

8.
Anc Sci Life ; 26(1-2): 89-91, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22557232

RESUMEN

Siddha is a traditional medical system of India. According to siddha system of medicine, chendooram is a red colour powder generally made of metallic compounds. Mercury is used in the form of rasa chendooram (red oxide of mercury). This paper deals with the standardization of Kantha chendooram. It is a Siddha preparation of 8 ingredients, viz. 1. Purified Lode Stone, 2. Purified Sulphur, 3. Lead wort root powder, 4. Eclipta juice, 5. Lime juice, 6. Milk, 7. Egg albumin, 8. Madar Latex. In this study an attempt was made to standardize Kantha chendooram which has not been attempted by researchers earlier. Standardization of Kantha chendooram was in terms of its organoleptic characters, qualitative identification of phytochemical constituents, metallic quantification and in terms of pharmacognostical standardization.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...